Literature DB >> 23561472

MBL versus CLL: how important is the distinction?

Lydia Scarfò1, Claudia Fazi, Paolo Ghia.   

Abstract

Monoclonal B-cell lymphocytosis (MBL) is defined as a clonal B-cell expansion whereby the B-cell count is less than 5 × 10(9)/L and no symptoms or signs of lymphoproliferative disorders are detected. Based on B-cell count, MBL is further divided into low-count and clinical MBL. While low-count MBL seems to carry relevance mostly from an immunological perspective, clinical MBL and chronic lymphocytic leukemia appear to be overlapping entities. Only a deeper knowledge of molecular pathways and microenvironmental influences involved in disease evolution will help to solve the main clinical issue, i.e. how to differentiate nonprogressive and progressive cases requiring intensive follow-up.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23561472     DOI: 10.1016/j.hoc.2013.01.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

1.  A prognostic algorithm including a modified version of MD Anderson Cancer Center (MDACC) score predicts time to first treatment of patients with clinical monoclonal lymphocytosis (cMBL)/Rai stage 0 chronic lymphocytic leukemia (CLL).

Authors:  Stefano Molica; Diana Giannarelli; Luciano Levato; Rosanna Mirabelli; Massimo Gentile; Mirella Lentini; Fortunato Morabito
Journal:  Int J Hematol       Date:  2014-07-27       Impact factor: 2.490

2.  Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines.

Authors:  Timothy G Call; Aaron D Norman; Curtis A Hanson; Sara J Achenbach; Neil E Kay; Clive S Zent; Wei Ding; James R Cerhan; Kari G Rabe; Celine M Vachon; Emily J Hallberg; Tait D Shanafelt; Susan L Slager
Journal:  Cancer       Date:  2014-04-07       Impact factor: 6.860

3.  The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL.

Authors:  Sameer A Parikh; Kari G Rabe; Neil E Kay; Timothy G Call; Wei Ding; Jose F Leis; Saad S Kenderian; Eli Muchtar; Yucai Wang; Amber B Koehler; Susan M Schwager; Connie E Lesnick; Geffen Kleinstern; Daniel Van Dyke; Curtis A Hanson; Esteban Braggio; Susan L Slager; Tait D Shanafelt
Journal:  Blood       Date:  2021-07-15       Impact factor: 25.476

4.  Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.

Authors:  B M Solomon; K G Chaffee; J Moreira; S M Schwager; J R Cerhan; T G Call; N E Kay; S L Slager; T D Shanafelt
Journal:  Leukemia       Date:  2015-08-27       Impact factor: 11.528

5.  Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome.

Authors:  Ignacio Criado; Arancha Rodríguez-Caballero; M Laura Gutiérrez; Carlos E Pedreira; Miguel Alcoceba; Wendy Nieto; Cristina Teodosio; Paloma Bárcena; Alfonso Romero; Paulino Fernández-Navarro; Marcos González; Julia Almeida; Alberto Orfao
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

6.  Monoclonal B-cell lymphocytosis.

Authors:  G D'Arena; P Musto
Journal:  Transl Med UniSa       Date:  2014-02-04

7.  Frequency of monoclonal B-cell lymphocytosis in relatives of patients with chronic lymphocytic leukemia.

Authors:  Rossana Villegas Gracia; Catalina Franco Alzate; Javier Rendón Henao; José Domingo Torres Hernández; Patricia Elena Jaramillo Arbelaez
Journal:  Colomb Med (Cali)       Date:  2016-06-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.